




FIG.1





FIG.2






FIG.4




FIG.5




FIG. 6




FIG. 7

Subgroup	Event/total Tidellzumab + chemotherapy	Event/total Placebo + chemotherapy	HR for PD (95% CI)	HR (95% CI)
Overall	176/227	207/230	*	0.63 (0.52-0.78)
Age Group				
<65 years	106/138	138/149	*	0.59 (0.45-0.77)
≥65 years	70/89	69/81	*	0.74 (0.53-1.05)
Sex				
Male	144/186	165/186	*	0.70 (0.56-0.88)
Female	32/41	42/44	*	0.38 (0.23-0.63)
ECOG performance status				
0	28/35	29/34	---	0.65 (0.39-1.10)
1	148/192	178/196	*	0.63 (0.50-0.79)
Smoking status				
Never	41/53	55/59	*	0.50 (0.22-0.77)
Smoker	135/174	152/171	*	0.68 (0.53-0.86)
AJCC staging at study entry				
III	14/20	25/29	---	0.50 (0.25-1.00)
IV	162/207	182/201	*	0.63 (0.50-0.78)
Liver metastasis				
Yes	52/64	56/69	*	0.71 (0.48-1.05)
No	124/163	151/171	*	0.60 (0.47-0.77)
Brain metastasis				
No	175/226	204/226	*	0.63 (0.51-0.78)
Baseline LDH				
≤ULN	91/114	97/109	*	0.63 (0.47-0.84)
>ULN	85/113	110/121	*	0.65 (0.48-0.87)
Choice of platinum				
Cisplatin	38/47	43/49	*	0.75 (0.48-1.18)
Carboplatin	138/180	164/181	*	0.61 (0.48-0.77)




FIG. 8




FIG. 9




FIG. 10




FIG. 11